Bridgehead modification of trihalocycloheptabenzopyridine lead to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability-Reference-Cited by-同舟云学术

Bridgehead modification of trihalocycloheptabenzopyridine lead to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability

Published:2004-12 Issue:23 Volume:14 Page:5899-5902
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Njoroge F. George,Vibulbhan Bancha,Shi Xiongwei,Strickland Corey,Kirschmeier Paul,Bishop Robert,Nomeir Amin,Girijavallabhan Viyyoor

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference20 articles.

1. Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development

2. Discovery and Advancement of Farnesyl Transferase Inhibitors as Potential Anticancer Therapeutic Agents: SCH 66336 a Case Study

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Recent Development of Farnesyltransferase Inhibitors as Anticancer and Antimalarial Agents;Mini-Reviews in Medicinal Chemistry;2015-06-19

2. Tricyclic Structures in Medicinal Chemistry: An Overview of their Recent Uses in Non-CNS Pathologies;Mini-Reviews in Medicinal Chemistry;2008-12-01

3. Farnesyl Protein Transferase Inhibitors: Medicinal Chemistry, Molecular Mechanisms, and Progress in the Clinic;Topics in Medicinal Chemistry;2006

4. Bridgehead Modification of Trihalocycloheptabenzopyridine Lead to a Potent Farnesyl Protein Transferase Inhibitor with Improved Oral Metabolic Stability.;ChemInform;2005-03-29